München

• A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended recruitment
  2024-510887-22-00 5 2019-09-30 Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irin … Halted
  2024-512951-18-00 4 2021-08-06 Hepatic Oligometastatic Adenocarcinoma of the Pancreas
• A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety … Suspended
  2024-511244-12-01 5 Amyotrophic Lateral Sclerosis
• A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended
  2024-516240-26-00 5 2024-10-11 Influenza
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 5 2024-04-10 Severe eosinophilic asthma
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended
  2022-500897-32-00 5 2023-11-02 Chronic pain due to diabetic polyneuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended
  2022-500898-13-00 5 2023-11-02 Chronic Pain due to traumatic or post-operative peripheral Neuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended
  2022-500899-66-00 5 2023-11-02 Chronic pain due to central Neuropathy of any Genesis
• Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended
  2022-502151-54-00 5 2023-11-02 Chronic back pain
• A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S … Ended
  2023-505558-16-00 5 2023-10-24 Atopic Dermatitis
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) Ended
  2022-502837-24-00 5 2023-09-25 Overweight
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen … Ended
  2022-501537-23-00 4 2023-05-16 Acute myeloid leukemia
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 4 2022-10-17 BRCA Mutations and Early Stage HER2-Negative Breast Cancer
• Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial Hypertension Ended
  2023-505541-99-00 4 2022-06-28 Pulmonary Arterial Hypertension
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment Ended
  2023-509141-12-00 4 2022-04-28 Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH

Showing 49–72 of 80 trials